27 related articles for article (PubMed ID: 18067834)
21. [C3d enhances immune response to the secreted form of Coxsackie virus B3 VP1 DNA vaccine].
Zhao N; Han XY; Wang XL; Li J; Li W; Xie LX; Li L; Wang YX
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(36):2561-3. PubMed ID: 18067834
[TBL] [Abstract][Full Text] [Related]
22. Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease.
Henke A; Jarasch N; Martin U; Wegert J; Wildner A; Zell R; Wutzler P
Int J Med Microbiol; 2008 Jan; 298(1-2):127-34. PubMed ID: 17897883
[TBL] [Abstract][Full Text] [Related]
23. Vaccination procedures against Coxsackievirus-induced heart disease.
Henke A; Jarasch N; Wutzler P
Expert Rev Vaccines; 2003 Dec; 2(6):805-15. PubMed ID: 14711363
[TBL] [Abstract][Full Text] [Related]
24. Complement 3d: from molecular adjuvant to target of immune escape mechanisms.
Bergmann-Leitner ES; Leitner WW; Tsokos GC
Clin Immunol; 2006 Nov; 121(2):177-85. PubMed ID: 16914381
[TBL] [Abstract][Full Text] [Related]
25. DNA plasmid based vaccination against the oncogenic human T cell leukemia virus type 1.
Agadjanyan MG; Wang B; Nyland SB; Weiner DB; Ugen KE
Curr Top Microbiol Immunol; 1998; 226():175-92. PubMed ID: 9479842
[No Abstract] [Full Text] [Related]
26. Targeting intracellular mediators of pattern-recognition receptor signalling to adjuvant vaccination.
Wales J; Andreakos E; Feldmann M; Foxwell B
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1501-3. PubMed ID: 18031253
[TBL] [Abstract][Full Text] [Related]
27.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
